Halozyme Therapeutics | HALO - Pre Tax Profit


Halozyme Therapeutics reported $180.33M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amarin USD -852K 7.26M Dec/2025
Amgen USD 1.51B 2.41B Dec/2025
Baxter International USD -756M 877M Dec/2025
Cara Therapeutics USD -4.91M 3.17M Mar/2025
Cytokinetics USD -206.03M 23M Mar/2026
DBV Technologies USD -33.16M 8.6M Sep/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Intrexon USD -60.48M 27.09M Jun/2024
Ionis Pharmaceuticals USD -93M 135M Mar/2026
MannKind USD -16.37M 4.56M Mar/2026
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
United Therapeutics USD 444M 6M Dec/2025
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024